Business
Agenus Provides R&D Update & Second Quarter Financial Report
- Dr. Chuck Drake & Dr. Bree Wilky to discuss AGEN1181 & zalifrelimab - new responses - AGEN2373 achieves durable SDs in early Ph1; balstilimab combos to
About this update from Agenus Inc.
[{"type":"text","content":"- Dr. Chuck Drake & Dr. Bree Wilky to discuss AGEN1181 & zalifrelimab - new responses\n - AGEN2373 achieves durable SDs in early Ph1; balstilimab combos to start\n - Zalifrelimab achieves responses in PD-1 failures (1CR, 3PRs); Ph2 expansion underway\n - Next-gen CTLA-4, PD-1 & iNKT activating therapy shows curative potential (AACR2020)\n - Renewably sourced QS-21 shows bio-equivalence; QS-21 enhances antibody titers in SARS-CoV-2 models\n - Partnership with Betta Pharmaceuticals for greater China rights to Bali/Zali closes with $35M in cash and equity, plus up to $100M in milestones plus royalties\n\n\nLEXINGTON, Mass., Aug. 6, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided an R&D and business update and reported financial results for the second quarter of 2020.\n\n \n \n \n \n \n \n\n \nBalstilimab BLA filing to be initiated in current quarter Balstilimab granted FTD and eligible for priority review Combo trial with zali completes accrual & required follow-up; BLA planning underwayZalifrelimab actives responses in PD-1 refractory tumors (1CR, 3PRs) Ph2 expansion trial in angiosarcoma underway; additional cancers to followAGEN1181 combo w bali achieves CR with both primary and metastatic tumors confirmed by PET scan Updated Ph1 achieves a total of 2 CRs & clinical benefit (CR/PR/SD) in ~65% patients Expansion cohorts in NSCLC, MSS tumors, melanoma, and RCC launched AGEN2373 achieves durable SD in ovarian, lung, sarcoma No liver toxicity observed AGEN2373 advancing to combo with balstilimab Production of QS-21 from a renewable source achieved and equivalence to QS-21 Saponin demonstrated High-yield process development underway Bioequivalence to first-generation demonstrated Enhanced antibody responses achieved in SARS-CoV-2 models Completed partnership with Betta Pharmaceuticals; $15M upfront, $20M equity investment, $100M in milestones & royalties Rights to balstilimab and zalifrelimab for Greater China Clinical development in major cancers being plannedFirst Quarter Financial ResultsWe ended the second quarter of 2020 with a cash balance of $79 million as compared to $62 million at December 31, 2019. Subsequent to the quarter end w...